Benign prostatic hyperplasia affects over 660 million men worldwide.1,2 While men can select from a variety of treatment options—from medication to major surgery—there has been a gap in the treatment continuum for a less invasive option.
Prostatic Urethral Lift using the UroLift® System was designed to meet this need. With its unique design and mechanism of action, the UroLift System is a treatment that provides immediate, visible results.3 The procedure can be done in an outpatient or day surgery setting and under general or local anesthesia.4 Patients typically can return home the same day without a catheter,4 and experience rapid symptom relief and recovery with low complication rates.3,4 The UroLift System treatment revitalises the quality of life for patients and improves the BPH therapy experience for physicians.5
The UroLift System uses a proven approach to treating BPH that lifts and holds the enlarged prostate tissue out of the way so it no longer blocks the urethra. It is the only leading BPH treatment that does not require heating, cutting, removal, or destruction of the prostate tissue.5-9
Treatment with the UroLift System typically takes less than one hour and does not preclude future UroLift System treatments, TURP, or laser procedures.5
The UroLift System is comprised of two main components:
Non-clinical testing has demonstrated that the UroLift Implant is MR Conditional. A patient with this device can be safely scanned in an MR system immediately after placement meeting the following conditions10:
Under the scan conditions defined above, the UroLift Implant is expected to produce a maximum temperature rise of 2.4°C after 15 minutes of continuous scanning (i.e., per pulse sequence).
The safety of the delivery system has not been evaluated in the MR environment, and therefore, the delivery system should not be used within the MR environment.
UroLift Implant
UroLift Delivery Device
Source Information
1. Berry, J Urol 1984
2. US Census Bureau international database worldwide population estimates for 2020
3. Roehrborn, J Urol 2013
4. AUA Guidelines 2003, 2020;
5. Roehrborn, Can J Urol 2017
6. Mirakhur, Can Assoc Rad J 2017;
7. McVary, J Urol 2016;
8. Gilling, Can J Urol 2020
9. Kadner, World J Urol
10. 10. UroLift System -Instructions for use, data on file
INFORMATION FOR PHYSICIANS ABOUT THE UROLIFT® SYSTEM
The UroLift System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100 cc in men 50 years or older. The UroLift implants are permanent and can be delivered during an outpatient procedure, relieving prostate obstruction without heating, cutting, destructing, or removing prostate tissue. The UroLift System can be used to treat a broad spectrum of anatomies, including obstructive median lobe.1 It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.*2-4 Most common side effects are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.5 Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure (using the UroLift System) is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines.
Contraindicated in men with a prostate volume greater than 100cc or a urinary tract infection.
† Warning: This device contains stainless steel and nitinol, an alloy of nickel and titanium. Persons with allergic reactions to these metals may suffer an allergic reaction to this implant. Prior to implantation, patients should be counseled on the materials contained in the device, as well as potential for allergy/hypersensitivity to these materials.
Individual results may vary. For full information, please consult the Instructions for Use (IFU)
*No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study.
Teleflex, BPH Relief In Sight and UroLift are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. ©2023 Teleflex Incorporated. All rights reserved. Revised: 02/2023. MC-008657 LA EN
Teleflex Medical Brasil Ltda
Rua Alexandre Dumas, 2100/132 - Chacara Santo Antonio
São Paulo/SP - CEP 04717-913
